All In Biotech

NDA 020267 · Haleon US Holdings

Junior Strength Advil

Ibuprofen · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 19, 2026Latest source record: Mar 29, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Dec 13, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

910

162 Phase 3, 61 recruiting

FAERS reports

201,373

146,632 serious, 16,449 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 22, 2024.

USES temporarily: • reduces fever • relieves minor aches and pains due to the common cold, flu, sore throat, headaches and toothaches

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 13, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
  • JUNIOR STRENGTH ADVIL · IBUPROFEN 100MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Ibuprofen" as an intervention, any sponsor and status, largest first.

All 910 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective15,947
  • pain15,216
  • fatigue14,696
  • nausea13,732
  • headache12,242
  • arthralgia11,062
  • dyspnoea10,662
  • vomiting10,136
  • diarrhoea9,837
  • rash9,148
  • off label use8,775
  • dizziness8,295

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,609
20052,142
20062,049
20072,110
20081,780
20092,765
20103,972
20115,698
20127,063
20136,774
20146,585
20159,139
201612,507
201711,355
201815,605
201916,698
202015,483
202115,284
202214,651
202313,680
202412,648
202512,810
20268,957

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,679 on PubMed

Sponsor: Haleon US Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.